Learning outcomes
By the end of this lesson you should be able to: contrast the pathology, reversibility and natural history of asthma and of chronic obstructive pulmonary disease; interpret spirometry including the post-bronchodilator ratio and the reversibility criterion; explain the physiology of air trapping and hyperinflation in obstructive disease; describe the stepwise treatment of asthma and the grouped assessment of chronic obstructive pulmonary disease; recognise the features of a life-threatening asthma attack and the place of oxygen, bronchodilators, steroids and magnesium; and list the indications for long-term oxygen therapy and non-invasive ventilation.
Prerequisites
PHYS 101 (airway resistance, lung volumes, the control of breathing and gas exchange), MED 301 lesson 2 (respiratory rate and oxygen saturation), lesson 6 (ABCDE and escalation), and PHRM 202 (beta-agonists, antimuscarinics and corticosteroids).
The big idea
Both diseases narrow the airways, but the narrowing is produced by different tissues and it behaves differently. In asthma the obstruction is largely within the lumen and the wall — smooth muscle contraction, mucus and mucosal oedema — and it reverses, both under treatment and between attacks. In chronic obstructive pulmonary disease the small airways are narrowed and destroyed, elastic recoil is lost, the bronchioles collapse on expiration, and the obstruction is fixed at least in part. That single distinction — variable versus fixed — is what the spirometer measures, and it is what the whole diagnostic vocabulary records.
The consequence of fixed obstruction is hyperinflation. If the airways collapse early on expiration, each breath leaves air behind, so the residual volume and total lung capacity rise and the diaphragm is flattened and mechanically disadvantaged. The patient breathes at a higher lung volume, with a smaller reserve for the next breath, which is why breathlessness in chronic obstructive pulmonary disease is effort-dependent and fixed, and why pursed-lip breathing — which raises airway pressure and keeps the bronchioles open — genuinely helps.
Comparing the two diseases
| Feature | Asthma | Chronic obstructive pulmonary disease |
|---|---|---|
| Typical onset | Childhood or young adulthood, often with a family history of atopy | Middle age or later, after 20 pack-years of smoking |
| Reversibility | Complete or near complete, variable from day to day, with diurnal variation | Partial or absent; some improvement with bronchodilator but a persistent obstruction |
| Symptoms | Episodic wheeze, cough and breathlessness, worse at night and in the early morning, with triggers (exercise, cold air, allergens, infection, aspirin) | Chronic cough and sputum, exertional breathlessness that progresses year on year, with wheeze |
| Airway inflammation | Eosinophilic and type 2 inflammation, with mast cell and lymphocyte involvement | Neutrophilic and macrophage inflammation, with mucosal gland hypertrophy and goblet cell hyperplasia |
| Parenchyma | Normal, unless coexisting disease | Emphysema: loss of alveolar walls, of surface area and of elastic recoil |
| Course | Variable with periods of remission; lung function normal between attacks | Progressive, with an accelerated decline unless smoking stops |
| Response to treatment | Marked, so that inhaled corticosteroids plus bronchodilators can normalise the airflow | Partial: bronchodilators and anti-inflammatory therapy modify symptoms and exacerbations rather than normalise the flow |
NoteAsthma and chronic obstructive pulmonary disease coexist in the same patient more often than textbooks imply, and the combination carries worse airflow limitation and more exacerbations than either alone. The diagnostic phrase 'asthma-COPD overlap' describes that reality, and its management leans toward the asthma side: always inhaled corticosteroids.
Diagnosis by spirometry
| Test | What it measures | Interpretation |
|---|---|---|
| FEV1 divided by FVC after a bronchodilator | The proportion of the vital capacity that can be exhaled in one second | A ratio below 0.70 confirms persistent airflow limitation in chronic obstructive pulmonary disease; in asthma the ratio is normal between attacks |
| Reversibility in asthma | The change in FEV1 15 minutes after a short-acting beta-agonist | A rise in FEV1 of at least 12 percent and at least 200 millilitres is significant reversibility, supporting asthma |
| Peak expiratory flow variability | Serial readings at home over two weeks | Diurnal variability above 20 percent in adults (or above 10 percent amplitude) supports a diagnosis of asthma |
| Carbon monoxide transfer factor | The efficiency of gas transfer across the alveoli | A reduced transfer factor indicates emphysema and loss of surface area, and helps separate emphysema from airway-predominant disease |
| Fractional exhaled nitric oxide | A marker of eosinophilic airway inflammation | A raised value supports type 2 asthma and predicts a response to inhaled corticosteroids |
| Response to a trial of treatment | Symptoms and spirometry after inhaled corticosteroids | In asthma, a therapeutic trial is both diagnostic and therapeutic; response confirms the diagnosis |
Two cautions belong beside the numbers. Spirometry performed during a severe acute attack is often poor quality and may be dangerous, so it is not used to grade severity in an emergency; and a normal resting ratio does not exclude asthma, because the obstruction is variable by definition. The patient with classic symptoms and a normal trace needs a peak flow diary or a provocation test rather than reassurance.
Asthma: stepwise treatment
| Step | Regimen | Situation |
|---|---|---|
| 1 | An inhaled short-acting beta-agonist used as required (or an as-needed inhaled corticosteroid-formoterol) | Intermittent symptoms, fewer than twice a week and no night waking |
| 2 | A daily low-dose inhaled corticosteroid (or a low-dose corticosteroid-formoterol used as both reliever and maintenance) | Any patient using a reliever more than twice a week, waking with symptoms, or with an exacerbation in the past two years |
| 3 | A low-dose inhaled corticosteroid plus a long-acting beta-agonist (or a medium-dose corticosteroid-formoterol as maintenance and reliever) | Symptoms persist on step 2, or an exacerbation despite adherence |
| 4 | A medium-dose inhaled corticosteroid plus a long-acting beta-agonist, with consideration of a leukotriene receptor antagonist or a long-acting muscarinic antagonist | Persistent symptoms, or repeated exacerbations |
| 5 | A high-dose inhaled corticosteroid plus a long-acting beta-agonist, with a referral for add-on therapy — a monoclonal antibody against IgE or interleukin 5, or a maintenance oral corticosteroid at the lowest dose | Severe asthma with continuing symptoms or exacerbations despite adherence at step 4 |
Two principles run through the ladder. First, the inhaled corticosteroid is the drug that changes the disease: it reduces symptoms, exacerbations and death, and it is never withdrawn from an asthmatic whose disease is not trivial. Second, adherence and technique are checked and corrected before any step is added, because a reliever used more than twice a week is a marker of uncontrolled disease and of poor inhaler technique far more often than of drug failure.
Watch outNever add a long-acting beta-agonist without an inhaled corticosteroid in asthma. Used alone, long-acting bronchodilators mask the inflammation, and the combination without a corticosteroid is associated with an increased risk of severe and fatal attacks.
Chronic obstructive pulmonary disease: assessment and treatment
| Domain | Assessment | Treatment |
|---|---|---|
| Symptoms | Modified Medical Research Council dyspnoea scale and the COPD Assessment Test, plus the number of exacerbations in the past year | Group A: a bronchodilator. Group B: two bronchodilators. Group E: two bronchodilators, with more exacerbation prevention, in anyone admitted with an exacerbation |
| Bronchodilation | A long-acting muscarinic antagonist (tiotropium) or a long-acting beta-agonist, alone or in combination | A long-acting muscarinic antagonist plus a long-acting beta-agonist reduces exacerbations more than either alone |
| Inhaled corticosteroid | Considered when the blood eosinophil count is raised (300 cells per microlitre or more) or when there are frequent exacerbations despite dual bronchodilation | Added to a long-acting beta-agonist and a muscarinic antagonist; raises the risk of pneumonia, so it is not given to everyone |
| Inhaled short-acting therapy | Used for relief and in acute exacerbations | Prescribed to every patient as a rescue, and reviewed for over-use which signals poor control |
| Non-pharmacological | Smoking cessation, vaccination (influenza, pneumococcal, COVID-19), pulmonary rehabilitation, weight and nutrition, occupational exposure | Smoking cessation is the only intervention that changes the rate of decline in lung function; pulmonary rehabilitation reduces breathlessness and readmission more effectively than any drug |
| Oxygen | Long-term home oxygen when the arterial oxygen tension is at or below 55 millimetres of mercury (7.3 kilopascals), or 59 or below with complications — oedema, polycythaemia or pulmonary hypertension | Given for at least 15 hours a day, and it improves survival in that group; the decision rests on blood gases, not on oxygen saturation |
| Ventilation | Non-invasive ventilation for persistent hypercapnic respiratory failure with an arterial pH of 7.35 or below and a carbon dioxide tension above 45 millimetres of mercury, two to four weeks after an exacerbation | Reduces mortality and readmission, and is started after recovery and after excluding obstruction as the cause of the carbon dioxide retention |
The inhaled corticosteroid question in chronic obstructive pulmonary disease is the mirror image of asthma: it is not the drug that changes the disease, and it is given to the subgroups in whom exacerbations are frequent or the eosinophil count is high, because in everyone else the pneumonia risk outweighs the benefit.
Acute exacerbations
| Life-threatening and severe asthma | Acute exacerbation of COPD | |
|---|---|---|
| First measures | High-flow oxygen to a saturation of 94 to 98 percent, and a nebulised short-acting beta-agonist driven by oxygen | Controlled or titrated oxygen to a target of 88 to 92 percent while arterial gases are obtained, plus nebulised bronchodilators |
| Bronchodilator | Repeated, or a continuous nebulised beta-agonist; add ipratropium bromide in severe attacks | A short-acting beta-agonist with a short-acting muscarinic antagonist, repeated as needed |
| Corticosteroid | Oral prednisolone 40 to 50 milligrams for at least 5 to 7 days, started within the first hour | Oral prednisolone 30 to 40 milligrams for 5 days |
| Additional measures | Intravenous magnesium sulphate in severe or refractory bronchospasm; consider parenteral beta-agonist, and ventilatory support when exhaustion develops | Antibiotics for increased sputum purulence with increased volume or dyspnoea; non-invasive ventilation when the pH is below 7.35 with a raised carbon dioxide |
| Features of life threat | A silent chest, a respiratory rate above 25, a pulse above 110, a peak flow below a third of the best, exhaustion, cyanosis, confusion, and a normal or rising arterial carbon dioxide | A silent chest, exhaustion with small tidal volumes, a rising carbon dioxide, a falling pH, oxygen saturation that cannot be corrected, and drowsiness |
| Disposition | A patient with any life-threatening feature is admitted, with the extreme cases admitted to intensive care | Admission for any life-threatening feature, for hypercapnia, or where home support is inadequate |
Watch outA normal or rising arterial carbon dioxide in an asthma attack is a sign of impending respiratory failure, because the tiring patient can no longer sustain the compensatory hyperventilation. It is one of the gravest findings on the blood gas and it mandates immediate ventilation support and intensive care review.
In chronic obstructive pulmonary disease the oxygen paradox deserves a clear statement, because the traditional warning has become muddled. Hypoxaemia kills, so oxygen is never withheld; but a patient with a chronically raised carbon dioxide may lose their hypoxic drive and develop carbon dioxide narcosis if given too much oxygen, so the target saturation of 88 to 92 percent is observed and the blood gases are checked. The correct response to a rising carbon dioxide in a COPD patient is ventilation support, not withdrawal of the oxygen they need.
NoteAntibiotics are not routine in an asthma exacerbation, but they are indicated in chronic obstructive pulmonary disease when sputum becomes purulent with increased volume or breathlessness, and in any exacerbation where ventilation support is needed.
Common mistakes
Watch outDiagnosing chronic obstructive pulmonary disease in a young wheezy patient, or asthma in a 70-year-old smoker, on the basis of a single symptom. The discriminator is spirometry, and the history is what decides whether the test is performed at all.
Watch outEscalating the drug step without checking adherence and inhaler technique. Poor inhaler technique is the commonest reason for uncontrolled asthma, and a reliever over-use tells you so.
Watch outWithholding oxygen from a COPD patient because of the carbon dioxide retention. The patient is titrated onto controlled oxygen to a target saturation of 88 to 92 percent, with arterial gases measured, and ventilation is used for the carbon dioxide.
Watch outReassurance from a normal peak flow at a clinic visit in a patient with episodic breathlessness. Spirometry between attacks may be normal in asthma, so a two-week peak flow diary or a provocation test is what establishes the diagnosis.
Check your understanding
Why is a high bicarbonate in a patient with chronic obstructive pulmonary disease a sign of chronic carbon dioxide retention rather than of a metabolic alkalosis?
A spirometer shows a post-bronchodilator FEV1 of 1.2 litres, an FVC of 3.0 litres and an FEV1 that rises 15 percent and by 250 millilitres after a bronchodilator. What does each number tell you?
Which features of an asthma attack indicate that the patient is tiring?
Multiple choice
Which spirometric finding confirms a diagnosis of chronic obstructive pulmonary disease?
Which finding in an acute asthma attack indicates a life-threatening episode?
Which is an indication for long-term home oxygen therapy in chronic obstructive pulmonary disease?
Which is the single most effective intervention to slow the decline in lung function in a patient with chronic obstructive pulmonary disease?
A patient with severe chronic obstructive pulmonary disease has an arterial pH of 7.28 with a carbon dioxide tension of 9.5 kilopascals, persisting after nebulised bronchodilators. What is the next treatment?
Module summary and next
Asthma and chronic obstructive pulmonary disease are the two obstructive lung diseases, separated by the variable versus fixed nature of the obstruction and by the tissue that produces it. Asthma is treated by anti-inflammatory therapy with a bronchodilator for relief; chronic obstructive pulmonary disease is treated by bronchodilation, risk-factor removal and rehabilitation, with inhaled corticosteroids reserved for exacerbating and eosinophilic phenotypes. Both are dangerous in their acute decompensations, and in both the danger is seen in the silent chest and in the failing blood gas.
Next: pneumonia and pleural disease — infection, effusion and air where they should not be, in which the severity score, the site of care and the pleural fluid are the three decisions that matter.